{"id":20765,"date":"2022-02-14T15:50:33","date_gmt":"2022-02-14T14:50:33","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=20765"},"modified":"2022-02-14T15:50:37","modified_gmt":"2022-02-14T14:50:37","slug":"mini-labs-to-track-and-treat-superbugs-sent-to-amr-blind-spots","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/mini-labs-to-track-and-treat-superbugs-sent-to-amr-blind-spots\/","title":{"rendered":"Mini-labs to track and treat superbugs sent to AMR \u2018blind spots\u2019"},"content":{"rendered":"\n<p>Article published on <a href=\"https:\/\/www.telegraph.co.uk\/global-health\/science-and-disease\/mini-labs-track-treat-superbugs-sent-amr-blind-spots\/\" target=\"_blank\" rel=\"noreferrer noopener\">The Telegraph<\/a> on February 04, 2022<\/p>\n\n\n\n<p>Scientists have created a compact, transportable mini-lab to help tackle antimicrobial resistance in remote regions<\/p>\n\n\n\n<p>Mini-labs tracking the spread of superbugs in remote regions could transform treatment and detection of antimicrobial resistance (AMR) in the world\u2019s \u201cblind spots\u201d, scientists say.<\/p>\n\n\n\n<p>AMR is an escalating health emergency across the globe, with\u00a0<a href=\"https:\/\/www.telegraph.co.uk\/global-health\/science-and-disease\/superbugs-killed-one-million-people-globally-2019-study-finds\/\" target=\"_blank\" rel=\"noreferrer noopener\">landmark estimates last month<\/a>\u00a0warning that at least 1.27 million people died due to resistant infections in 2019 alone.\u00a0<\/p>\n\n\n\n<p>Although the highest burden is in sub Saharan Africa and South Asia, patchy surveillance across these regions has made it tricky to assess the true scale of the health crisis.&nbsp;<\/p>\n\n\n\n<p>But now, scientists at M\u00e9decins Sans Fronti\u00e8res (MSF) have created a \u201ccompact, transportable, affordable\u201d mini-lab to help medics diagnose and treat resistant bacterial infections \u2013 such as sepsis, urinary tract infections and\u00a0<a href=\"https:\/\/www.telegraph.co.uk\/global-health\/science-and-disease\/new-hope-patients-gruelling-treatment-drug-resistant-tb-could\/\" target=\"_blank\" rel=\"noreferrer noopener\">tuberculosis<\/a>.\u00a0<\/p>\n\n\n\n<p>Dr Jean-Baptiste Ronat, an MSF microbiologist who has\u00a0<a href=\"https:\/\/www.clinicalmicrobiologyandinfection.com\/article\/S1198-743X(21)00198-1\/fulltext\" target=\"_blank\" rel=\"noreferrer noopener\">led the mini-lab project<\/a>, said his team has effectively squeezed a hi-tech laboratory into six containers. This takes two days to set up and needs a space no larger than 20 square metres. The NGO offers two to three months of onsite training so local lab technicians can run and maintain the kit.<\/p>\n\n\n\n<p>\u201cWhat we have developed is not a low-level laboratory,\u201d Dr Ronat told\u00a0<em>The Telegraph<\/em>. \u201cIt is the same quality as you would find in high income countries, but adapted to the local context.\u201d<\/p>\n\n\n\n<p>He added that a full, transportable lab where every component has been adjusted to suit a lower income setting has never been produced before, and it was an \u201cintense\u201d feat to condense a complex microbiology lab into half a dozen transportable crates.&nbsp;<\/p>\n\n\n\n<p>While the lab is expensive \u2013 current models cost in the ballpark of \u00a340,000 \u2013 this is a fraction of the price of a full microbiology lab, which can be well over \u00a3200,000. MSF added that it is confident the cost will \u201cdecrease further when in full production\u201d.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Central African Republic gets a mini-lab<\/h2>\n\n\n\n<p>The mini-lab project was first launched in 2016, and an\u00a0<a href=\"https:\/\/www.clinicalmicrobiologyandinfection.com\/article\/S1198-743X(21)00198-1\/fulltext\" target=\"_blank\" rel=\"noreferrer noopener\">initial nine month trial completed in Haiti in April 2020<\/a>. Now, a second generation prototype has been set up in Carnot \u2013 a small city in the Central African Republic (CAR), some 300 miles west from the capital Bangui.\u00a0<\/p>\n\n\n\n<p>Like many lower income countries the CAR, which is home to roughly five million people, has an \u201cenormous\u201d lack of capacity to track AMR, with just a couple of laboratories in the capital.&nbsp;<\/p>\n\n\n\n<p>Experts are therefore \u201cflying blind\u201d about the scale of AMR in areas outside Bangui, Dr Ronat said, with doctors unable to identify superbug outbreaks or provide those with resistant infections with the most suitable antibiotics.&nbsp;<\/p>\n\n\n\n<p>\u201cAnd so that\u2019s why this will make such a difference. We do not know the exact extent of AMR outside urban centres in many low and middle income countries; huge areas are just blind spots,\u201d Dr Ronat said. \u201cThis will also help clinicians to adapt the treatment based on the infection they are treating.\u201d<\/p>\n\n\n\n<p>In December alone, the Carnot mini-lab cultured around 380 blood samples, of which around 12 per cent were found to be positive for bacterial growth, and 18 per cent of this bacteria where found to be resistant to antibiotics.<\/p>\n\n\n\n<p>\u201cSo now AMR is everywhere \u2013 you open Pandora\u2019s box by putting in a lab, and you see there is AMR,\u201d Dr Ronat, who has led the mini-lab team since the project was first launched, said.\u00a0<\/p>\n\n\n\n<p>He also warned that the burden of AMR is likely to overtake health threats including HIV and malaria in the coming years \u2013 but is even more challenging to tackle.&nbsp;<\/p>\n\n\n\n<p>\u201cAMR is such a complex issue,\u201d he said. \u201cIn these regions, it\u2019s due to a lack of hygiene, a lack of infrastructure, a lack of medical policy \u2013 the fact you can go in Carnot to a pharmacy and get whatever antibiotics.\u201d<\/p>\n\n\n\n<p>On a global scale, Dr Ronat added, the lack of new antibiotics presents a ticking time bomb. According to the World Health Organization,\u00a0<a href=\"https:\/\/www.telegraph.co.uk\/global-health\/science-and-disease\/antibiotic-pipeline-offers-little-hope-counter-silent-pandemic\/\" target=\"_blank\" rel=\"noreferrer noopener\">none of the 43 antibiotics currently in clinical development<\/a>\u00a0\u201csufficiently address\u201d rising drug-resistance in the world\u2019s most dangerous 13 pathogens.\u00a0<\/p>\n\n\n\n<p>The mini-labs project is currently seeking wider investment to expand its remit and coverage &nbsp;with aims to set up in countries including South Sudan, Iraq, Bangladesh and the Democratic Republic of Congo, said C\u00e9line Franquesa, project manager of the mini-lab programme.<\/p>\n\n\n\n<p>\u201cIf we are able in three years to be able to deploy, let\u2019s say 15 mini-labs within MSF, we would be glad because then we would be able to have a real surveillance network,\u201d she told The Telegraph. \u201cAnd we hope to make it accessible outside MSF too, this is part of the work we are doing this year.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Article published on The Telegraph on February 04, 2022 Scientists have created a compact, transportable mini-lab to help tackle antimicrobial resistance in remote regions Mini-labs tracking the spread of superbugs in remote regions could transform treatment and detection of antimicrobial resistance (AMR) in the world\u2019s \u201cblind spots\u201d, scientists say. AMR is an escalating health emergency [&hellip;]<\/p>\n","protected":false},"author":139,"featured_media":20771,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[31],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Mini-labs to track and treat superbugs sent to AMR \u2018blind spots\u2019 - Interface nationale ANTIBIOR\u00c9SISTANCE<\/title>\n<meta name=\"description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/mini-labs-to-track-and-treat-superbugs-sent-to-amr-blind-spots\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mini-labs to track and treat superbugs sent to AMR \u2018blind spots\u2019 - Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"og:description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/mini-labs-to-track-and-treat-superbugs-sent-to-amr-blind-spots\/\" \/>\n<meta property=\"og:site_name\" content=\"Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"article:published_time\" content=\"2022-02-14T14:50:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-02-14T14:50:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/02\/Labo-Africa.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"895\" \/>\n\t<meta property=\"og:image:height\" content=\"582\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u00c9milie Noguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u00c9milie Noguez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/mini-labs-to-track-and-treat-superbugs-sent-to-amr-blind-spots\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/mini-labs-to-track-and-treat-superbugs-sent-to-amr-blind-spots\/\"},\"author\":{\"name\":\"\u00c9milie Noguez\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\"},\"headline\":\"Mini-labs to track and treat superbugs sent to AMR \u2018blind spots\u2019\",\"datePublished\":\"2022-02-14T14:50:33+00:00\",\"dateModified\":\"2022-02-14T14:50:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/mini-labs-to-track-and-treat-superbugs-sent-to-amr-blind-spots\/\"},\"wordCount\":796,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/mini-labs-to-track-and-treat-superbugs-sent-to-amr-blind-spots\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/02\/Labo-Africa.jpg\",\"articleSection\":[\"Actualit\u00e9s\"],\"inLanguage\":\"fr-FR\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/mini-labs-to-track-and-treat-superbugs-sent-to-amr-blind-spots\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/mini-labs-to-track-and-treat-superbugs-sent-to-amr-blind-spots\/\",\"name\":\"Mini-labs to track and treat superbugs sent to AMR \u2018blind spots\u2019 - Interface nationale ANTIBIOR\u00c9SISTANCE\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/mini-labs-to-track-and-treat-superbugs-sent-to-amr-blind-spots\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/mini-labs-to-track-and-treat-superbugs-sent-to-amr-blind-spots\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/02\/Labo-Africa.jpg\",\"datePublished\":\"2022-02-14T14:50:33+00:00\",\"dateModified\":\"2022-02-14T14:50:37+00:00\",\"description\":\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/mini-labs-to-track-and-treat-superbugs-sent-to-amr-blind-spots\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/mini-labs-to-track-and-treat-superbugs-sent-to-amr-blind-spots\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/mini-labs-to-track-and-treat-superbugs-sent-to-amr-blind-spots\/#primaryimage\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/02\/Labo-Africa.jpg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/02\/Labo-Africa.jpg\",\"width\":895,\"height\":582,\"caption\":\"Cr\u00e9dit : Pixabay\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/mini-labs-to-track-and-treat-superbugs-sent-to-amr-blind-spots\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Infos pratiques &amp; communications\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Actualit\u00e9s\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Mini-labs to track and treat superbugs sent to AMR \u2018blind spots\u2019\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"name\":\"Interface nationale ANTIBIOR\u00c9SISTANCE\",\"description\":\"PPR Antibior\u00e9sistance - Inserm\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\",\"name\":\"\u00c9milie Noguez\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mini-labs to track and treat superbugs sent to AMR \u2018blind spots\u2019 - Interface nationale ANTIBIOR\u00c9SISTANCE","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/mini-labs-to-track-and-treat-superbugs-sent-to-amr-blind-spots\/","og_locale":"fr_FR","og_type":"article","og_title":"Mini-labs to track and treat superbugs sent to AMR \u2018blind spots\u2019 - Interface nationale ANTIBIOR\u00c9SISTANCE","og_description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/mini-labs-to-track-and-treat-superbugs-sent-to-amr-blind-spots\/","og_site_name":"Interface nationale ANTIBIOR\u00c9SISTANCE","article_published_time":"2022-02-14T14:50:33+00:00","article_modified_time":"2022-02-14T14:50:37+00:00","og_image":[{"width":895,"height":582,"url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/02\/Labo-Africa.jpg","type":"image\/jpeg"}],"author":"\u00c9milie Noguez","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"\u00c9milie Noguez","Dur\u00e9e de lecture estim\u00e9e":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/mini-labs-to-track-and-treat-superbugs-sent-to-amr-blind-spots\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/mini-labs-to-track-and-treat-superbugs-sent-to-amr-blind-spots\/"},"author":{"name":"\u00c9milie Noguez","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3"},"headline":"Mini-labs to track and treat superbugs sent to AMR \u2018blind spots\u2019","datePublished":"2022-02-14T14:50:33+00:00","dateModified":"2022-02-14T14:50:37+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/mini-labs-to-track-and-treat-superbugs-sent-to-amr-blind-spots\/"},"wordCount":796,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/mini-labs-to-track-and-treat-superbugs-sent-to-amr-blind-spots\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/02\/Labo-Africa.jpg","articleSection":["Actualit\u00e9s"],"inLanguage":"fr-FR"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/mini-labs-to-track-and-treat-superbugs-sent-to-amr-blind-spots\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/mini-labs-to-track-and-treat-superbugs-sent-to-amr-blind-spots\/","name":"Mini-labs to track and treat superbugs sent to AMR \u2018blind spots\u2019 - Interface nationale ANTIBIOR\u00c9SISTANCE","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/mini-labs-to-track-and-treat-superbugs-sent-to-amr-blind-spots\/#primaryimage"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/mini-labs-to-track-and-treat-superbugs-sent-to-amr-blind-spots\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/02\/Labo-Africa.jpg","datePublished":"2022-02-14T14:50:33+00:00","dateModified":"2022-02-14T14:50:37+00:00","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/mini-labs-to-track-and-treat-superbugs-sent-to-amr-blind-spots\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/mini-labs-to-track-and-treat-superbugs-sent-to-amr-blind-spots\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/mini-labs-to-track-and-treat-superbugs-sent-to-amr-blind-spots\/#primaryimage","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/02\/Labo-Africa.jpg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/02\/Labo-Africa.jpg","width":895,"height":582,"caption":"Cr\u00e9dit : Pixabay"},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/mini-labs-to-track-and-treat-superbugs-sent-to-amr-blind-spots\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/"},{"@type":"ListItem","position":2,"name":"Infos pratiques &amp; communications","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/"},{"@type":"ListItem","position":3,"name":"Actualit\u00e9s","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/"},{"@type":"ListItem","position":4,"name":"Mini-labs to track and treat superbugs sent to AMR \u2018blind spots\u2019"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","name":"Interface nationale ANTIBIOR\u00c9SISTANCE","description":"PPR Antibior\u00e9sistance - Inserm","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3","name":"\u00c9milie Noguez"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-27 19:52:14","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/20765"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/users\/139"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/comments?post=20765"}],"version-history":[{"count":8,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/20765\/revisions"}],"predecessor-version":[{"id":20785,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/20765\/revisions\/20785"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media\/20771"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media?parent=20765"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/categories?post=20765"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/tags?post=20765"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}